- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06057025
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
September 26, 2023 updated by: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Safety, Reactogenicity and Immunogenicity Study of the Drug "Sputnik Lite" for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Composition With Participation of Adult Volunteers.
Safety, reactogenicity and immunogenicity study of the drug "Sputnik Lite" for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of adult volunteers.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
The study will include volunteers who meet all the specified criteria:
- Subject's written informed consent to participate in the study;
- Adult volunteer's men and women over 18 years old;
- A negative test result for COVID-19, determined by PCR or express method before the introduction of the investigational medicinal product (IMP).
- Consent to the use of effective methods of contraception during the entire period of participation in the study;
- A negative pregnancy test based on the results of a urine test at a screening visit (for women with preserved reproductive potential);
- Negative test for the presence of narcotic and psychostimulants in the urine at the screening visit;
- Negative alcohol content test at the screening visit;
- No contraindications to vaccination;
- Absence of acute infectious and/or respiratory diseases for at least 14 days prior to inclusion in the study.
Exclusion Criteria:
Volunteers cannot be included in the study if there is at least one of the following criteria for non-inclusion:
- No signed informed consent to participate in the study;
- Therapy with steroids (with the exception of hormonal contraceptives and/or hormone replacement therapy) and / or immunoglobulins or other blood products that did not end 30 days before inclusion in the study;
- Therapy with any immunosuppressive drugs completed less than 3 months before inclusion in the study;
- Female subjects during pregnancy or lactation;
- Acute coronary syndrome or stroke suffered less than one year before inclusion in the study;
- Tuberculosis, chronic systemic infections according to anamnesis;
- Burdened allergic anamnesis (the presence in the anamnesis of information about anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness), hypersensitivity or allergic reactions to the administration of immunobiological drugs, known allergic reactions to the components of the drug, exacerbation of allergic diseases on the day of inclusion in the study;
- The presence of neoplasms (ICD codes C00-D09) (according to the anamnesis);
- Splenectomy (according to the anamnesis);
- Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l), immunodeficiency - 6 months prior to inclusion in the study (according to the anamnesis);
- Subjects with an active form of the disease caused by human immunodeficiency virus, syphilis, hepatitis B and C (according to anamnesis);
- Anorexia, protein deficiency of any origin;
- Alcoholism and drug addiction (according to anamnesis);
- The subject's participation in any other interventional clinical trial (with the exception of rescreening in the current study) in the last 90 days;
- Extensive tattoos at the injection sites (deltoid muscle area), which do not allow to assess the local reaction to the introduction of investigational medicinal product (IMP);
- Any other condition of the subject of the study, which, in the opinion of the research doctor, may prevent the completion of the study in accordance with the protocol;
- Vaccination against COVID-19 or transmitted coronavirus infection COVID-19 less than 6 months before screening;
- Repeated administration of the Sputnik V vaccine, Sputnik Lite, or repeated administration of any other COVID-19 vaccine for more than three injections (Sputnik V vaccination plus Sputnik Lite revaccination);
- Inability to read in Russian; inability or unwillingness to understand the essence of the study;
- Any other conditions that limit the validity of obtaining informed consent or may affect the ability of the volunteer to participate in the study, affect the ability of the volunteer to participate in the study;
- Staff of research centers (chief researcher and members of the research team) directly involved in the research and their family members.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy patients
Drug: Sputnik Light vector vaccine for the prevention of coronavirus infection caused by the SARS CoV-2 virus (with altered antigenic composition); A total of 50 people will be randomized and receive the study drug.
A single intramuscular injection of the investigational medicinal product (IMP) will be performed.
|
Biological: "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition
Single intramuscular injection of "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events (AE)
Time Frame: Within 28 days after administration of the drug
|
Occurrence of adverse events (AE)
|
Within 28 days after administration of the drug
|
Occurrence of serious adverse events (SAEs)
Time Frame: Throughout Study completion, until December 2024
|
Occurrence of serious adverse events (SAEs)
|
Throughout Study completion, until December 2024
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
September 21, 2023
First Submitted That Met QC Criteria
September 26, 2023
First Posted (Actual)
September 28, 2023
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 26, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14-Sputnik Lite / N-2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition
-
Gamaleya Research Institute of Epidemiology and...Not yet recruiting
-
Gamaleya Research Institute of Epidemiology and...Not yet recruiting
-
Federal Budgetary Research Institution State Research...CompletedCovid19Russian Federation
-
Federal Budgetary Research Institution State Research...Completed
-
Federal Budgetary Research Institution State Research...Completed
-
University of MilanLuigi Sacco University HospitalCompletedCOVID19 | BETA-CELL FUNCTIONItaly
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.; Weill Medical College of Cornell UniversityCompletedGastric Cancer | Esophageal CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedNeuroblastomaUnited States